Evidence map›Paper›PMID 23892229›Full record

ArticleNeurobiology of disease2013

Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection.

Hua Shen, Krzysztof L Hyrc, Mark P Goldberg

Open access · greenAbstract read
In one paragraph

Article in Neurobiology of disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Basic Pathological Mechanisms in Peripheral Nerve Diseases.International journal of molecular sciences · 2025
    Review
  3. NADAntioxidants & redox signaling · 2023
    Review
  4. Review
  5. Review
  6. NADCell insight · 2022
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Structural and Functional Rescue of Chronic Metabolically Stressed Optic Nerves through Respiration.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  12. Article
  13. Article
  14. The β-NADOncotarget · 2017
    Article
  15. Glucose metabolism in nerve terminals.Current opinion in neurobiology · 2017
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hua ShenHope Center for Neurological Disorders and Department of Neurology, Washington University School of Medicine, 660 S. Euclid Avenue, Saint Louis, MO 63110, USA. Electronic address: hshen22@wustl.edu.
Krzysztof L Hyrc
Mark P Goldberg
Hope Center for Neurological Disorders · USWashington University in St. Louis · US

Funding

Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
ZINC AND ISCHEMIC BRAIN INJURYP01NS032636 · NINDS · WASHINGTON UNIVERSITY · PI LEE, JIN-MOO · 1995 to 2010
$13.2M
Washington University Center for Translational NeuroscienceP30NS057105 · NINDS · WASHINGTON UNIVERSITY · PI HOLTZMAN, DAVID M. · 2006 to 2011
$8.7M
OLIGODENDROCYTE DEATH IN CEREBRAL ISCHEMIAR01NS036265 · NINDS · WASHINGTON UNIVERSITY · PI GOLDBERG, MARK PAUL · 1997 to 2007
$1.7M
NCATS NIH HHS UL1 TR000448NINDS NIH HHS NS057105NINDS NIH HHS P01 NS032636NINDS NIH HHS P30 NS057105NINDS NIH HHS R01 NS036265
6 · The paper itself

Abstract

Wld(S) mutation protects axons from degeneration in diverse experimental models of neurological disorders, suggesting that the mutation might act on a key step shared by different axon degeneration pathways. Here we test the hypothesis that Wld(S) protects axons by preventing energy deficiency commonly encountered in many diseases. We subjected compartmentally cultured, mouse cortical axons to energy deprivation with 6mM azide and zero glucose. In wild-type (WT) culture, the treatment, which reduced axon ATP level ([ATP]axon) by 65%, caused immediate axon depolarization followed by gradual free calcium accumulation and subsequent irreversible axon damage. The calcium accumulation resulted from calcium influx partially via L-type voltage-gated calcium channel (L-VGCC). Blocking L-VGCC with nimodipine reduced calcium accumulation and protected axons. Without altering baseline [ATP]axon, the presence of Wld(S) mutation significantly reduced the axon ATP loss and depolarization, restrained the subsequent calcium accumulation, and protected axons against energy deprivation. Wld(S) neurons possessed higher than normal nicotinamide mononucleotide adenylyltransferase (NMNAT) activity. The intrinsic Wld(S) NMNAT activity was required for the Wld(S)-mediated energy preservation and axon protection during but not prior to energy deprivation. NMNAT catalyzes the reversible reaction that produces nicotinamide adenine dinucleotide (NAD) from nicotinamide mononucleotide (NMN). Interestingly, preventing the production of NAD from NMN with FK866 increased [ATP]axon and protected axons from energy deprivation. These results indicate that the Wld(S) mutation depends on its intrinsic Wld(S) NMNAT activity and the subsequent increase in axon ATP but not NAD to protect axons, implicating a novel role of Wld(S) NMNAT in axon bioenergetics and protection.

Indexed as

Adenosine TriphosphateAnimalsAxonsCalciumCerebral CortexDisease Models, AnimalEmbryo, MammalianEnergy MetabolismEnzyme ActivationEnzyme InhibitorsGlucoseMembrane PotentialsMiceMice, Inbred C57BLMitochondriaMutationAdenosine TriphosphateCalciumEnzyme InhibitorsGlucoseNerve Tissue ProteinsSodium AzideWld protein, mousearea under the curveATP[ATP](axon)[ATP](cell)ATP level in axonsATP levels in cell bodiesAUCAxon injuryBioenergeticsbis(1,3-dibutylbarbituric acid) trimethine oxonol[Ca(2+)](axon)Calciumdays in vitroDFIDibac(4)(3)Dibac(4)(3) fluorescence intensityDIVEnergy deprivationfree calcium concentration in axonGAgallotanninhours post injuryhpiL-type voltage-gated calcium channelL-VGCCMitoTracker Red CMXRosMTRNADNAMNAMPTnicotinamidenicotinamide adenine dinucleotidenicotinamide mononucleotidenicotinamide mononucleotide adenylyltransferasenicotinamide phosphoribosyltransferaseNMNNMNATphosphoribosylpyrophosphatePPiPRPPpyrophosphateregion of interestROIwild-typeWld(S)WT

Identifiers

PMID23892229
PMCPMC3787137
OpenAlexW1973403076

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.